

## AMENDMENT

Please amend the claims as set out below. This listing of claims will replace all previous versions.

1. (Currently amended) A tripeptide ~~or tetrapeptide~~ or an alkyl ester thereof comprising a proteolytic enzyme cleavable amino acid moiety that is connect to as a drug or pharmacologically active site or pharmacologically active group ~~transport and delivery system with the proviso that it is not prolyl-m-sarcolysyl-p-fluoro-phenylalanine.~~

2. (Currently amended) The tripeptide ~~or tetrapeptide~~ of claim 1, which is an alkyl ester with the alkyl group being a methyl or an ethyl group, preferably an ethyl group.

3. (Currently amended) The tripeptide ~~or tetrapeptide~~ of claim 1, wherein the proteolytic enzyme cleavable amino acid moiety is a not terminal moiety.

4. (Currently amended) The tripeptide ~~or tetrapeptide~~ of claim 1 comprising a not terminal optionally substituted phenylalanyl moiety.

5. (Currently amended) The tripeptide ~~or tetrapeptide~~ of claim 1 ~~anyone of the preceding claims~~ that is selected from the group consisting of substituted or unsubstituted Phe-Phe-Pro, Pro-Phe-Phe, Phe-Phe-Ser, Ser-Phe-Phe, Phe-Phe-Asn, Asn-Phe-Phe, Phe-Gly-Phe-Val (Seq. Id. No. 1), Val-Phe-Gly-Phe (Seq. Id. No. 2), Phe-Arg-Phe-His (Seq. Id. No. 3), His-Phe-Arg-Phe (Seq. Id. No. 4), Phe-Arg-Val, Val-Arg-Phe, and Pro-Phe-Phe.

6. (Currently amended) The tripeptide ~~or tetrapeptide~~ of claim 1, wherein the terminal Phe is fluoro substituted in para position[[,]] ~~in particular the peptide Pro-Phe-p-F-Phe.~~

7. (Currently amended) The tripeptide ~~or tetrapeptide~~ of claim 1 wherein the proteolytic enzyme cleavable amino acid moiety is substituted with a substituent sufficiently reactive to be useful in drug coupling reactions, with the proviso that said substituent is not --N(CH<sub>2</sub>—CH<sub>2</sub>--Cl)<sub>2</sub> in meta position on the not terminal Phe of Pro-Phe-p-F-Phe.

8. (Currently amended) The tripeptide ~~or tetrapeptide~~ of claim 7 wherein the proteolytic enzyme cleavable amino acid moiety is or comprises Phe.

9. (Canceled)

10. (Canceled)

11. (Currently amended) The tripeptide ~~or tetrapeptide~~ of claim ~~10~~ 1 wherein the drug is adriamycin.

12. (Canceled)

13. (Canceled)

14. (Canceled)

15. (Canceled)

16. (Currently amended) A pharmaceutical composition comprising a tripeptide ~~or a tetrapeptide~~ of claim ~~10~~ 1.

17. (Canceled)

18. (Currently amended) The tripeptide ~~or tetrapeptide~~ of claim 1 that is a substituted or unsubstituted Pro-Phe-Phe.

19. (Canceled)

20. (New) The tripeptide of claim 6 wherein the peptide is Pro-Phe-p-F-Phe.